Clinic News Latest in CardiologyREDEFINE 1 and REDEFINE 2: Greater Weight Loss With Combined Cagrilintide-Semaglutide vs. Either Drug Alone or PlaceboThe combination of cagrilintide with semaglutide (CagriSema) in a single weekly injection was associated with a significantly greater weight loss in adults with overweight or obesity regardless of type 2 diabetes (T2D) status compared with placebo or either drug alone...Starting DOACs Early After Stroke Lowers Risk of Future Strokes, HemorrhageInitiating direct oral anticoagulants (DOACs) within four days, rather than at five days or later, after an ischemic stroke in patients with atrial fibrillation (AFib) reduced the risk of future stroke events within 30 days without increasing symptomatic intracerebral hemorrhage...Poll: Transcatheter Mitral Valve Replacement in a High Surgical Risk Patient With Mitral StenosisMrs. M is an 81-year-old female patient who presents with worsening exertional dyspnea. She has a history of type 2 diabetes mellitus, heart failure with preserved ejection fraction, and prior surgical aortic valve replacement in the setting of severe symptomatic aortic stenosis.PRAGUE-25: What Is the Best Intervention Strategy For AFib In Obesity?Catheter ablation (CA) was superior to a combination of lifestyle modification (LFM) and antiarrhythmic drugs (AADs) in improving freedom from atrial fibrillation (AFib) at one year in patients with obesity, according to results from the PRAGUE-25 trial published in JACC.June AMA House of Delegates Key TakeawaysThe American Medical Association (AMA) House of Delegates met in June to discuss and vote on the latest round of proposed resolutions aimed at guiding AMA’s policies on key medical, ethical and public health issues.SWISS-APERO: Similar 3-Year Ischemic Risk With Amulet vs. Watchman FLXWhile there was no significant difference in ischemic risk in patients with atrial fibrillation between the Amulet and Watchman FLX devices at three years following left atrial appendage closure (LAAC), according to findings from the SWISS-APERO trial published in JACC...ACCEL Lite: Hemodynamic Assessment for Diagnosis and Treatment Selection in HFpEFIn this interview, Drs. Matthew Martinez and Barry Borlaug discuss “Hemodynamic Assessment for Diagnosis and Treatment Selection in HFpEF.â€Editors' Corner | Bridging Innovation and PracticeDigital health technologies (DHTs) – from remote patient monitoring and virtual care to AI-powered data analysis – hold significant promise for enhancing the prevention, diagnosis and treatment of cardiovascular disease.Cover Story | The Future of Digital Health in Cardiovascular Disease: Bridging Innovation and Clinical PracticeCardiovascular diseases, including cardiometabolic diseases and related conditions, are the leading causes of death and disability worldwide. Despite advances in pharmacological treatments, significant gaps remain in achieving optimal cardiometabolic health, with disparities and barriers to accessing care.Feature | The Overlooked Cardiac Implications of Alpha-Gal SyndromeAlpha-Gal Syndrome (AGS) is an underrecognized, tick-borne allergic condition with emerging relevance in cardiovascular medicine. Sensitization to galactose-α-1,3-galactose (alpha-gal), a mammalian-derived carbohydrate absent in humans and other primates, occurs following tick bites...
